Molecular and clinical aspects of embryotoxicity induced by acetylcholinesterase inhibitors

J Tsiaoussis; E Hatzidaki; A O Docea; T K Nikolouzakis; D Petrakis; T Burykina; C Mamoulakis; A Makrigiannakis; A Tsatsakis

doi:10.1016/j.tox.2018.07.018

Molecular and clinical aspects of embryotoxicity induced by acetylcholinesterase inhibitors

Toxicology. 2018 Nov 1:409:137-143. doi: 10.1016/j.tox.2018.07.018. Epub 2018 Jul 25.

Authors

J Tsiaoussis¹, E Hatzidaki², A O Docea³, T K Nikolouzakis⁴, D Petrakis⁵, T Burykina⁶, C Mamoulakis⁷, A Makrigiannakis⁸, A Tsatsakis⁹

Affiliations

¹ Laboratory of Anatomy-Histology-Embryology, Medical School, University of Crete, Voutes, 71110, Heraklion, Crete, Greece. Electronic address: tsiaoussis@uoc.gr.
² Department of Neonatology, University of Crete, Voutes, 71110, Heraklion, Crete, Greece. Electronic address: elhatzidaki@gmail.com.
³ Department of Toxicology, University of Medicine and Pharmacy, Faculty of Pharmacy, Craiova, 200349, Romania. Electronic address: ancadocea@gmail.com.
⁴ Laboratory of Anatomy-Histology-Embryology, Medical School, University of Crete, Voutes, 71110, Heraklion, Crete, Greece. Electronic address: tknikolouzakis@gmail.com.
⁵ Department of Forensic Sciences and Toxicology, Medical School, University of Crete, Voutes, 71003, Heraklion, Crete, Greece. Electronic address: demetriospetrakis@hotmail.com.
⁶ Department of Analytical and Forensic Medical Chemistry, Sechenov University, 119991, Moscow, Russian Federation.
⁷ Department of Urology, University General Hospital of Heraklion, University of Crete, Medical School, 71003, Heraklion, Crete, Greece. Electronic address: mamoulak@uoc.gr.
⁸ Department of Obstetrics and Gynecology, Medical School, University of Crete, 71003, Heraklion, Crete, Greece. Electronic address: makrygia@uoc.gr.
⁹ Department of Forensic Sciences and Toxicology, Medical School, University of Crete, Voutes, 71003, Heraklion, Crete, Greece. Electronic address: tsatsaka@uoc.gr.

PMID: 30055296
DOI: 10.1016/j.tox.2018.07.018

Abstract

Acetylcholinesterase inhibitors are widely used for a variety of medical, agricultural and public health purposes. Consequently, exposure is highly possible during lifetime. However, their systematic use raises concerns for the potential impact on the fetus and newborn since these substances may affect angiogenesis, the neonatal and maternal intensive care, neuroimmune function and response, mammary growth/lactation via cholinergic/non-cholinergic central and peripheral neuroendocrine pathways. New methodologies, neuroscientific technologies and research studies are needed to harness existing knowledge along with the proper management, availability for new acetylcholinesterase inhibitors, with stable pharmacodynamics and clinical outcomes.

Keywords: Cholinesterase inhibitors; Endocrine disruptors; Fetus; Organophosphates; Parasympathomimetics; Toxicity.

MeSH terms

Animals
Cholinesterase Inhibitors* / pharmacology
Cholinesterase Inhibitors* / therapeutic use
Embryo, Mammalian / drug effects*
Embryo, Mammalian / physiology
Humans
Teratogens / pharmacology

Substances

Cholinesterase Inhibitors
Teratogens